Overview

Key Figures1

kEUR

2022

2021

Change

 

 

 

 

Revenue

280,978

282,126

-0.4%

Custom Projects

140,044

167,006

-16.1%

Contract Manufacturing

110,753

89,600

23.6%

Generics & Cosmetics

30,181

25,520

18.3%

EBITDA

38,670

84,848

-54.4%

Adjusted 2 EBITDA

38,670

88,199

-56.2%

Adjusted 2 EBITDA in % of revenue

13.8%

31.3%

-17.5 ppts

Operating result (EBIT)

12,607

64,165

-80.4%

Operating result (EBIT) in % of revenue

4.5%

22.7%

-18.3 ppts

Result for the year

7,767

47,258

-83.6%

Result for the period in % of revenue

2.8%

16.8%

-14.0 ppts

Earnings per share (EUR), basic

0.24

1.47

-84.0%

Return on net operating assets (RONOA)

3.2%

21.0%

-17.8 ppts

Cash and cash equivalents (end of period)

37,528

136,303

-72.5%

Net cash flow from operating activities

5,460

57,352

-90.5%

Capital expenditures

82,985

76,652

8.3%

Capital expenditures in % of revenue

29.5%

27.2%

2.4 ppts

Total assets (end of period)

575,782

595,038

-3.2%

Equity ratio (end of period)

73.2%

70.8%

2.5 ppts

Employees (# of FTEs, average)

1,139

1,041

9.5%

1 This table and report include references to operational indicators and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.

2 For 2022, no EBITDA adjustments were recognized. Adjusted EBITDA for 2021 excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic.

This website uses cookies to ensure you get the best experience on our website.Privacy statement